Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · lyophilized powder, vial

Epic Peptides Lab · USA

Document number: PL-SDS-052
Revision: 1.0 · 2026-10-03

Erythropoietin (rhEPO)

lyophilized powder, vial

WARNING

1Identification

Product Identifier

Document Number

PL-SDS-052

Catalogue Items Covered

Id
2235
Name
EPO (Erythropoietin) 3000IU
Sku
PL-EPO-3000IU-VIAL

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Reproductive toxicity — Category 2 — H361

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H361 Suspected of damaging fertility or the unborn child.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Lyophilized (freeze-dried) powder or cake in a sealed glass vial with a rubber stopper and aluminium crimp cap.

Composition

Name
Erythropoietin (rhEPO)
Full
Recombinant human erythropoietin, epoetin class
Cas
11096-26-7
Formula
C809H1301N229O240S5 (165-residue protein core)
Conc
≥ 95% (dry basis, as supplied)
Qty
3000 IU per vial
Hazards
- Reproductive toxicity — Category 2 — H361

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.

5Fire-fighting measures

Fire Fighting Information: Combustible organic solid; finely divided powder may form dust clouds. Not flammable in the quantities supplied.

6Accidental release measures

Spill And Clean Up Procedures: Avoid dust formation. Dampen spilled powder with water, wipe up with absorbent material, place in a sealed container for disposal and clean the area with water and detergent.

7Handling and storage

Safe Handling: Open vials only in a clean area. Avoid generating or inhaling dust; weigh or reconstitute inside a ventilated enclosure when the full contents are handled as a dry powder. Reconstitute by adding diluent slowly to the vial wall; do not shake. Wash hands after handling.
Safe Storage: Store the sealed vial at the temperature stated in Section 9 (typically −20 °C for peptides, 2–8 °C for proteins), desiccated and protected from light. Allow the vial to reach room temperature before opening to avoid condensation. Reconstituted solutions: 2–8 °C, protected from light; use within the period established by your laboratory.
Storage Temperature: 2–8 °C (sealed vial); −20 °C for long-term storage; protected from light and moisture
Incompatible Materials: No information available; proteases; denaturants

8Exposure controls / personal protection

Occupational Exposure Limits: No data available.
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Solid

Appearance

White lyophilized powder or cake

Properties

Odor: No information available
Ph: Not applicable (solid); aqueous solutions typically pH 4–7
Melting: No information available (protein; denatures on heating)
Boiling: Not applicable (Procrit solution: 100 °C as aqueous)
Flash: Not applicable (non-flammable solid); combustible organic material
Vapour: Negligible (solid)
Density: No data available (bulk density of lyophilized cake is low)
Solubility: Soluble in water/PBS; reconstitute lyophilized protein in sterile water at 0.1-1 mg/mL (Invitrogen)
Logp: Not applicable
Decomp: No data available; peptides decompose above about 200 °C
Other: Glycoprotein, 165 amino acids, ~30.4 kDa glycosylated (18.2-18.4 kDa protein core); 3 N- and 1 O-glycosylation sites; expressed in CHO or HEK293 cells.

10Stability and reactivity

Stability And Reactivity

Reactivity: Stable under recommended storage conditions; no dangerous reaction known under normal use (Amgen, J&J)
Incompatible: No information available (Amgen); generic for proteins: strong acids, bases, oxidizing agents, proteases, denaturants
Decomposition: No information available; combustion gives carbon oxides, nitrogen oxides, sulfur oxides
Conditions To Avoid: Overheating, light exposure (J&J); freezing of solutions; repeated freeze-thaw; vigorous shaking (denaturation)

Conditions To Avoid

Overheating, light exposure (J&J); freezing of solutions; repeated freeze-thaw; vigorous shaking (denaturation)

Incompatible Materials

No information available; proteases; denaturants

11Toxicological information

Toxicological Information: Acute toxicity, oral
No information available (Amgen); no adverse effect in acute animal toxicity tests at >20,000 IU/kg (J&J Procrit); no LD50 values

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
Does not meet GHS classification criteria (Amgen)

Serious eye damage/irritation
Does not meet GHS classification criteria (Amgen)

Respiratory or skin sensitisation
No data available (J&J); Amgen: does not meet criteria. Recombinant protein powders are potential respiratory sensitisers - see notes

Germ cell mutagenicity
Not genotoxic based on a battery of in vitro and in vivo studies (Amgen)

Carcinogenicity
Not listed by IARC, NTP or OSHA (J&J); not classified (Amgen). Clinical remark: ESAs carry boxed warnings for tumour progression/shortened survival in some cancer patients

Reproductive toxicity
J&J Procrit: 'Potential embryo-foetal toxicity and teratogenicity'; adverse fertility effects in rodents - basis for H361. Amgen: does not meet classification criteria

STOT, single exposure
No data available

STOT, repeated exposure
J&J target organs: blood, central nervous system, cardiovascular system, immune system (pharmacological: polycythaemia, hypertension, thrombosis, pure red cell aplasia via anti-EPO antibodies) - not classified as STOT RE

Aspiration hazard
Not applicable
Routes Of Exposure: Inhalation of dust, skin and eye contact when the vial is opened or the powder is weighed; ingestion through contaminated hands; accidental injection when reconstituted solutions are drawn into syringes.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: No information available for toxicity, persistence, bioaccumulation or mobility (Amgen, J&J). Protein - expected to be biodegradable and of low aquatic toxicity.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Not listed (biologic protein; not on TSCA inventory)
Carcinogen Listings: Not listed by IARC, NTP, OSHA; not on California Prop 65 (Amgen: 'does not contain any Proposition 65 chemicals')
Dea: Not scheduled
Other: WADA: EPO and all erythropoiesis-stimulating agents prohibited at all times (S2) - remark only. Approved biologic (epoetin alfa/beta etc.) when GMP-manufactured as a drug; research-grade material is RUO. Not a controlled substance.

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Amgen

Janssen / Johnson & Johnson

Sigma-Aldrich E5546

R&D Systems / Bio-Techne 287-TC
Confidence: medium
Additional Information: Lyophilised recombinant or purified protein. Inhalation of protein dusts can sensitise susceptible individuals; avoid generating dust and handle the dry powder in a ventilated enclosure. Not classified for respiratory sensitisation because no substance-specific data exist.

WADA Prohibited List class S2.

Back to SDS list